Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study

Martin Hutchings*, Rogier Mous, Michael Roost Clausen, Peter Johnson, Kim M. Linton, Martine E.D. Chamuleau, David John Lewis, Anna Sureda, David Cunningham, Roberto S. Oliveri, Brian Elliott, Dena DeMarco, Ada Azaryan, Christopher Chiu, Tommy Li, Ko-Mei Chen, Tahamtan Ahmadi, Elly Lugtenburg

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

48 Citations (Scopus)
Original languageEnglish
Pages (from-to)1157-1169
JournalThe Lancet
Volume398
Issue number10306
Early online date23 Sep 2021
DOIs
Publication statusPublished - 25 Sep 2021

Cite this